PolyPid Ltd. (NASDAQ:PYPD) Sees Significant Growth in Short Interest

PolyPid Ltd. (NASDAQ:PYPD) was the recipient of a large growth in short interest in the month of March. As of March 31st, there was short interest totaling 44,212 shares, a growth of 94.8% from the March 15th total of 22,697 shares. Approximately 0.3% of the company’s shares are short sold. Based on an average daily trading volume, of 61,674 shares, the days-to-cover ratio is presently 0.7 days.

Analysts Set New Price Targets

Several research analysts have commented on PYPD shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of PolyPid in a report on Monday, December 29th. Wall Street Zen raised PolyPid from a “sell” rating to a “hold” rating in a report on Saturday, March 14th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $13.00 target price on shares of PolyPid in a report on Wednesday, February 11th. Five research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $12.25.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. ADAR1 Capital Management LLC bought a new position in shares of PolyPid in the 4th quarter worth about $451,000. XTX Topco Ltd raised its position in shares of PolyPid by 50.0% in the 4th quarter. XTX Topco Ltd now owns 32,661 shares of the company’s stock worth $142,000 after acquiring an additional 10,888 shares in the last quarter. Jane Street Group LLC bought a new stake in PolyPid in the 4th quarter valued at about $66,000. HighTower Advisors LLC bought a new stake in PolyPid in the 4th quarter valued at about $44,000. Finally, BNP Paribas Financial Markets increased its position in PolyPid by 56.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 9,734 shares of the company’s stock valued at $32,000 after buying an additional 3,500 shares in the last quarter. 26.47% of the stock is owned by institutional investors.

PolyPid Stock Performance

PYPD stock opened at $4.31 on Monday. The stock has a 50-day moving average price of $4.34 and a 200-day moving average price of $4.06. PolyPid has a 1-year low of $2.44 and a 1-year high of $5.12. The firm has a market cap of $82.23 million, a PE ratio of -1.91 and a beta of 1.45.

PolyPid (NASDAQ:PYPD) last posted its quarterly earnings data on Wednesday, February 11th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.07). On average, analysts forecast that PolyPid will post -1.79 earnings per share for the current year.

PolyPid Company Profile

PolyPid Ltd is a clinical‐stage biotechnology company focused on polymer‐based drug delivery technologies designed to enhance the performance of therapeutic agents at mucosal surfaces. Leveraging its proprietary Mucoadhesive & Mucus‐Penetrating (MMP) platform, PolyPid develops long‐acting formulations for ocular, oral and pulmonary indications. Its lead candidates include OncoTears and OralTear, therapies targeting dry eye and dry mouth conditions, respectively, as well as Paclical, a polymer‐formulated paclitaxel designed to improve tolerability and antitumor activity in oncology patients.

Founded in 2003 and headquartered in Jerusalem, Israel, PolyPid has assembled an international patent portfolio covering key markets in North America, Europe and Asia.